Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE - Free Report) to a sell rating in a report published on Tuesday.

Pulse Biosciences Trading Up 5.3 %

Shares of NASDAQ PLSE traded up $0.93 during mid-day trading on Tuesday, reaching $18.33. The company had a trading volume of 118,108 shares, compared to its average volume of 199,912. The firm has a 50 day simple moving average of $17.93 and a two-hundred day simple moving average of $16.66. Pulse Biosciences has a 52-week low of $6.59 and a 52-week high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the firm earned ($0.19) earnings per share.

Insiders Place Their Bets

In related news, Director Robert W. Duggan purchased 56,054 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $17.35 per share, with a total value of $972,536.90. Following the completion of the acquisition, the director now directly owns 42,228,057 shares in the company, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Burke Thomas Barrett sold 50,000 shares of the business's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the transaction, the chief executive officer now directly owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 71.50% of the stock is currently owned by insiders.

Institutional Trading of Pulse Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after purchasing an additional 9,639 shares in the last quarter. Rhumbline Advisers increased its position in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after purchasing an additional 1,608 shares during the period. Quest Partners LLC purchased a new position in shares of Pulse Biosciences during the 2nd quarter worth approximately $91,000. Creative Planning lifted its holdings in shares of Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after buying an additional 11,667 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after buying an additional 97,565 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.